Thank you for being a Global Market News subscriber.
Today’s Top Stories:
🛒
Costco’s New Purchase Limit Exposes a Bigger Inflation Problem
Costco is limiting purchases of an everyday product that recently sold for roughly $30 to $35 and now costs $57.99. The reason behind the restriction says a lot about where inflation is still hiding and why it may be harder to kill than the headline numbers suggest.
💡Sponsor Spotlight
An 8,000X Oversubscription Could Lift Robotics Stocks
Hold onto your nuts… and bolts: Robotics is having a moment that could be life-changing for many people. But an opportunity to get in changes on 9/17.
A recent robotics IPO was oversubscribed 8,000x. And experts say the frenzy could reprice robot company stocks industry-wide.
Meanwhile 40k+ everyday investors just like you have already backed private-stage up-and-comer Miso Robotics.
Miso’s Flippy Fry Station robot already has a $4b/year annual revenue potential. Now, Miso’s two 2026 acquisitions added big-name partners like Jersey Mike’s and grew its patent portfolio 10x overnight.
You too can be a shareholder at just $5.48/share, but not for long.
This is a paid advertisement for Miso Robotics' Regulation A offering. Please read the offering circular at invest.misorobotics.com
📈
Gold Is Doing Something It Shouldn’t. Here’s What It Could Be Telling Investors
Gold is behaving strangely, and inflation may no longer be the best explanation. The more important signal could be coming from the Treasury market and what investors increasingly believe about the Fed.
💡Sponsor Spotlight
Primary Care Physicians Miss Up to 46% of Skin Cancers. An FDA-Cleared, AI-Powered Device Is Closing the Gap.
DermaSensor holds the only FDA De Novo Clearance for AI-powered skin cancer detection in primary care, a regulatory head start no competitor can match. Ten health systems and hundreds of practices are already signed on a recurring subscription model, so the revenue keeps compounding.
Now, they’re expanding to Europe with 3x contracted revenue achieved from EOY 2024 to 2025 and another 3x increase projected this year.
You can invest at the same terms as their Series B investors now – a rare opportunity in medtech – but the allocation is almost gone.
🏦
The CLARITY Act Is Finally Getting a Senate Vote. Does It Even Matter Anymore?
After months of delays, the Senate is finally voting on the CLARITY Act. But while Washington was arguing, crypto markets, Wall Street and regulators kept moving. The bigger question now is whether this long-awaited bill still matters as much as investors think.
💡Sponsor Spotlight
Your Insurance Company Is Counting on You Not Shopping Around.
Many drivers simply renew their policy without checking whether a better rate is available.
This free tool compares quotes from more than 100 insurers in minutes, helping you see if you could save before your next bill arrives.
No obligation.
No phone calls required.
Know what you own, and know why you own it.
-Peter Lynch
You are receiving this email because you opted in to receive updates from Global Market News. This newsletter may contain sponsored content or advertisements. Information provided is for informational purposes only and should not be considered financial or investment advice. Always consult a financial advisor before making investment decisions.